208655-19-0

Basic information

• Product Name: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)
• Synonyms: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI);(2S)-2-BENZYLPIPERAZINE;2(S)-Benzylpiperazine;Piperazine, 2-(phenylmethyl)-, (2S)-;(S)-2-BENZYL-PIPERAZINE 2HCl;(2S)-2-(Phenylmethyl)-piperazine;(S)-2-Benzylpiperazinedihydrochloride
• CAS NO: 208655-19-0
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.25814
• Product Categories: PIPERIDINE
• Mol File: 208655-19-0.mol

Chemical Properties

• Boiling Point: 293°C at 760 mmHg
• Flash Point: 165.8°C
• Appearance: /
• Density: 0.996g/cm³
• Vapor Pressure: 0.00178mmHg at 25°C
• Refractive Index: 1.526
• PKA: 9.25±0.40(Predicted)
• CAS DataBase Reference: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(208655-19-0)
• EPA Substance Registry System: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(208655-19-0)

Safety Data

• Hazardous Substances Data: 208655-19-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Piperazine, 2-(phenylmethyl)-, (2S)(9CI) is used as a chiral building block for the synthesis of various pharmaceutical drugs. Its unique structure and chiral properties make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Drug Discovery:
Piperazine, 2-(phenylmethyl)-, (2S)(9CI) is utilized as a starting material or intermediate in the drug discovery process. Its potential to form novel chemical entities with specific biological activities makes it a promising candidate for the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
Piperazine, 2-(phenylmethyl)-, (2S)(9CI) serves as a research tool in medicinal chemistry, aiding scientists in understanding the structure-activity relationships of various compounds. Its chiral nature and potential interactions with biological targets make it an interesting subject for further investigation.

InChI:InChI=1/C11H16N2/c1-2-4-10(5-3-1)8-11-9-12-6-7-13-11/h1-5,11-13H,6-9H2/t11-/m0/s1

Upstream product

• 5037-75-2 cyclo(Gly-Phe) 

Downstream Products

• 1354376-46-7 C₁₄H₁₉N₃ 
• 1064651-76-8 5-(3(S)-benzyl-piperazin-1-yl)-8-(2-naphthyl)-7-(pyridin-4-yl)-1,2,4-triazolo[4,3-c]pyrimidine 
• 942123-11-7 3-(S)-benzyl-1-(4-bromo-benzyl)-piperazine 
• 848553-41-3 10-(S)-(3-benzylpiperazin-1-yl)-2-methyl-4H-3-thia-9-azabenzo[f]azulene 
• 1308375-51-0 3-((R)-2-amino-2-phenylethyl)-5-((S)-3-benzylpiperazin-1-yl)-1-(2,6-difluorobenzyl)-6-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor

The invention provides a histone demethylase LSD1 (lysine specific demethylase 1) inhibitor. The invention relates to piperazine-containing compounds and pharmacologically acceptable salts thereof and use of the piperazine-containing compounds and pharmacologically acceptable salts thereof as the LSD1 inhibitor; the general structural formula of the piperazine-containing compounds is described in the description. The invention belongs to the field of pharmaceutical chemistry. An in-vitro LSD1 activity inhibition test proves that the piperazine-containing compounds implemented by the invention have an obvious inhibiting effect for LSD1 activity, thus being used as active ingredients for preparing LSD1 inhibitor medicines.

COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, and the preparation and use thereof. The compounds are valuable CB2 receptor modulators.

SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES

A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS

Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted w

BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS

The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, R1, R2, R3, R4, R5, R5', R6, R6', R7, R7', R8, and R8' are as described in the specification.